Why Do People Sweat During Opioid Withdrawal?

Sweating during opioid withdrawal is a direct result of the autonomic nervous system going into overdrive when opioids are suddenly removed. Opioids suppress the locus coeruleus, a brain region that regulates norepinephrine release and autonomic activity. When opioids are removed, the locus coeruleus becomes hyperactive, flooding the body with norepinephrine — the neurotransmitter that activates fight-or-flight responses including sweating, rapid heart rate, and elevated blood pressure. This autonomic hyperactivity is why opioid withdrawal mimics a severe flu with profuse sweating, chills, goosebumps, and elevated body temperature. The body essentially swings to the opposite extreme from the suppression it experienced during active opioid use.

The Muse Treatment page lists several other withdrawal symptoms that accompany sweating: shakiness, cravings, stomach issues (nausea, vomiting, diarrhea), difficulty breathing, runny nose, watery eyes, yawning, insomnia, muscle aches, and anxiety. Opioid withdrawal is frequently compared to an intense flu — physically unpleasant and exhausting but rarely immediately life-threatening in physically healthy adults, unlike alcohol or benzodiazepine withdrawal. The combination of sweating, chills, muscle aches, and gastrointestinal distress makes the experience profoundly uncomfortable, which is one of the most common reasons people relapse — not from lack of willpower, but to stop the physical suffering of withdrawal.

The timeline of opioid withdrawal sweating depends on the specific opioid — whether it is short-acting (heroin, oxycodone, hydrocodone) or long-acting (methadone, buprenorphine). For short-acting opioids, withdrawal typically begins within 6 to 24 hours of the last dose, peaks around 36 to 72 hours, and largely resolves within one to two weeks. The Muse Treatment page notes that the safest approach is to work with an addiction treatment facility offering detox services, because monitoring and medication can significantly reduce the duration and severity of withdrawal symptoms including sweating. For long-acting opioids like methadone, withdrawal may be more gradual but can last several weeks.

The Muse Treatment page explicitly identifies attempting to detox from opioids at home as a potentially fatal mistake for many people. While opioid withdrawal is less immediately physically dangerous than alcohol withdrawal (seizures and delirium tremens are not typical opioid withdrawal features), the combination of severe physical discomfort, intense psychological distress, and powerful cravings makes relapse extremely likely without professional support. Moreover, the reduced tolerance that develops during even a brief abstinence means that returning to a previous dose after withdrawal can be fatal — many opioid overdose deaths occur shortly after a period of abstinence. Medically supervised detox significantly reduces this risk by providing medication, monitoring, and support through the most vulnerable period.

Several medications significantly reduce the sweating and other symptoms of opioid withdrawal. Clonidine, an alpha-2 adrenergic agonist, directly addresses the norepinephrine hyperactivity driving withdrawal symptoms — including sweating, anxiety, and elevated heart rate. Buprenorphine and methadone, used in medication-assisted treatment for opioid use disorder, can manage withdrawal symptoms by providing partial or full opioid receptor activation under medical supervision, allowing a gradual, controlled reduction rather than abrupt cessation. Anti-nausea medications, anti-diarrheal agents, and sleep aids may also be used to manage specific symptoms. The Muse Treatment page notes that medication-assisted treatment can help patients navigate withdrawal less traumatically while remaining focused on recovery goals.

Medication-assisted treatment (MAT) for opioid addiction combines FDA-approved medications — buprenorphine (Suboxone), methadone, or naltrexone — with counseling and behavioral therapies. Buprenorphine and methadone reduce cravings and withdrawal symptoms by activating opioid receptors partially or fully, stabilizing brain chemistry without producing the intense high of street opioids. Naltrexone blocks opioid receptors, preventing the euphoric effects of opioids if they are used. The Muse Treatment page describes MAT as something that can help patients navigate the withdrawal process in a less traumatic manner while remaining focused on recovery goals. MAT is the evidence-based standard of care for opioid use disorder and significantly reduces overdose mortality and relapse rates.

Relapse during or immediately after opioid withdrawal is extremely common and is driven by multiple overlapping factors: the intense physical discomfort of withdrawal (using eliminates the misery immediately), powerful psychological cravings, the reduced tolerance that develops during even brief abstinence (making overdose risk higher than during active use), environmental cues that trigger conditioned drug-seeking behavior, and inadequate professional support to help manage the withdrawal period. The Muse Treatment page notes that people often attempt to go through withdrawal at home feeling it might be more comfortable, but this is often when relapse occurs. Professional support during the acute withdrawal period dramatically reduces relapse risk by managing the physical symptoms and providing therapeutic accountability.

Opioid withdrawal involves the body's attempt to recalibrate after being suppressed by opioids for an extended period. Beyond sweating, virtually every opioid-suppressed system rebounds: the gastrointestinal system (which opioids slow dramatically) goes into overdrive, causing cramping, nausea, vomiting, and diarrhea. The pain system, suppressed by opioids, becomes hypersensitive — causing muscle aches and an overall experience of extreme physical discomfort. The emotional regulation system, previously mediated by opioid-induced endorphin effects, becomes dysregulated, causing intense anxiety and dysphoria. Sleep architecture is profoundly disrupted. Together, these effects create one of the most physically and psychologically uncomfortable withdrawal syndromes, though they are rarely immediately life-threatening with proper management.

Yes — for many people with opioid use disorder, medication-assisted treatment with buprenorphine (Suboxone) or methadone allows stable, indefinitely maintained treatment that prevents withdrawal entirely, rather than requiring a complete detox. In this model, the person takes their prescribed medication daily and experiences neither withdrawal nor the highs of illicit opioids, while engaging in therapy and building recovery skills. This approach has the strongest evidence base for reducing overdose mortality, HIV transmission, and other harms associated with opioid use disorder. The goal is not necessarily indefinite medication use — many people eventually taper off with appropriate support — but elimination of the dangerous forced withdrawal model that too often leads to relapse and overdose.

Muse Treatment offers medically supervised opioid detox that addresses the physical dimension of opioid withdrawal — including sweating, nausea, pain, and anxiety — with appropriate medication management while simultaneously beginning the therapeutic work of addiction recovery. The clinical team provides around-the-clock monitoring and support during the most vulnerable period of withdrawal, ensuring both safety and the best possible comfort. Following detox, Muse Treatment's comprehensive rehabilitation program — including behavioral therapy, group support, dual diagnosis treatment, and holistic wellness approaches — addresses the psychological and social dimensions of opioid use disorder. The Muse Treatment page emphasizes that detox is only the first step in a comprehensive recovery journey, not a complete treatment in itself.